« Previous
Next »
Titles
- PEPFAR: 20 years of progress, partnership, and impact1
- Parents with low incomes faced greater health challenges and problems accessing and affording needed health care in Spring 20211
- Parents’ intentions to vaccinate children for COVID-19 by child age: sociodemographic factors and reasons for hesitancy1
- Part D plans generally include drugs commonly used by dual eligibles: 20221
- Part D plans generally include drugs commonly used by dual-eligible enrollees: 20231
- Participation: who are the eligible but unenrolled?1
- Partners in vaccination: promoting COVID-19 vaccination for medically fragile adults1
- Patient engagement in the design and conduct of medical device clinical studies: guidance for industry, Food and Drug Administration staff, and other stakeholders1
- Patients diagnosed with post-COVID conditions: an analysis of private healthcare claims using the official ICD-10 diagnostic code1
- Patients find hospital systems deliver on care coordination, efficiency and access1
- Paving the way to health equity: learning from California state government1
- Payment integrity: additional coordination is needed for assessing risks in the improper payment estimation process for advance premium tax credits : report to congressional requesters1
- Payment reform1
- Pennsylvania could better ensure that nursing homes comply with federal requirements for life safety, emergency preparedness, and infection control1
- Pennsylvania implemented our prior audit recommendations for critical incidents involving Medicaid enrollees with developmental disabilities but should continue to take action to reduce unreported incidents1
- Perceptions of beneficiaries with mental illness and family representative payees regarding satisfaction and challenges1
- Perinatal health among Medicaid beneficiaries in North Carolina, 20181
- Peripheral percutaneous transluminal angioplasty (PTA) and specialty catheters: premarket notification (510(k)) submissions : guidance for industry and Food and Drug Administration staff1
- Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry1
- Plain and clear: making Medi-Cal communications easy to understand1